<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Granulocyte-macrophage colony-stimulating factor (GM-CSF) was given concurrently with low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> for 3 weeks to patients with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Neutrophil activation as evidenced by increased chemiluminescence and reduced surface expression of CD16 was consistently seen during therapy </plain></SENT>
<SENT sid="2" pm="."><plain>An attendant fall in chemotaxis was also observed </plain></SENT>
<SENT sid="3" pm="."><plain>These effects occurred even when neutrophil counts did not rise significantly at lower doses of GM-CSF </plain></SENT>
<SENT sid="4" pm="."><plain>Although no improvement in <z:hpo ids='HP_0001903'>anaemia</z:hpo> or <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> was observed, the neutrophil counts became <z:mpath ids='MPATH_458'>normal</z:mpath> during therapy without significant expansion of marrow cellularity or colony-forming ability </plain></SENT>
<SENT sid="5" pm="."><plain>No major toxicities were observed, even at higher dosages of GM-CSF </plain></SENT>
</text></document>